Tirzepatide

Understanding the timeline for weight loss on Zepbound, factors influencing results, and what to expect on your journey.

Zepbound (tirzepatide) is one of the most effective pharmaceutical weight loss treatments available. This article covers its dual GLP-1/GIP mechanism, the SURMOUNT trial evidence, side effects, who qualifies, and how it compares to other GLP-1 medications.

Several medications treat type 2 diabetes while producing significant weight loss. GLP-1 agonists and SGLT2 inhibitors lead the evidence base. This article covers the clinical trial data, NICE approval status, and how different drug classes affect both weight and blood glucose.

A clear, evidence-based guide to the FDA-approved weight loss injections available in 2025 — how they work, how effective they are, who qualifies, and what to expect.

Three injectable weight loss medications are licensed in the UK: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro). Head-to-head trial data shows tirzepatide produces the greatest weight loss (~20.9%), followed by semaglutide (~14.9%), then liraglutide (~8.4%). This article compares them across efficacy, side effects, dose schedule, and UK licensing.